异基因造血干细胞移植后的免疫相关研究进展

doi:10.3969/j.issn.1006-5725.2025.05.004

Abstract

Abstract:

Allogeneic hematopoietic stem cell transplantation （allo-HSCT） is a therapeutic approach that restores hematopoietic and immune functions in recipients through the infusion of allogeneic hematopoietic stem cells. It has evolved into an effective form of adoptive cellular immunotherapy， offering curative potential for various diseases， including malignant hematologic disorders， hematopoietic failure syndromes， congenital immunodeficiencies， and genetic metabolic disorders. Immunology plays a pivotal role in allo-HSCT， as post-transplant immunobiology is uniquely characterized by the potential for immune recognition and attack between donor and host cells. This review elucidates the distinctive features of immune reconstitution following allo-HSCT， examines the immunological underpinnings of graft-versus-host disease （GVHD） and the graft-versus-leukemia （GVL） effect， and evaluates how novel therapeutic strategies modulate these immune responses to improve the management of transplant-related complications and enhance patient outcomes. Additionally， the review addresses the challenges in balancing GVHD and GVL effects and outlines potential directions for future research.

Key words: hematopoietic stem cell transplantation, immunological mechanisms, malignant hematological diseases

CLC Number:

R392.4

Xingchi CHEN,Xiaoyu. ZHU. Advances in immunological research on hematopoietic stem cell transplantation[J]. The Journal of Practical Medicine, 2025, 41(5): 641-647.

References 56

1	ROMMELEY M， SPIES-WEISSHART B， SCHILLING K， et al. Reconstitution and functional analyses of neutrophils and distinct subsets of monocytes after allogeneic stem cell transplantation［J］. J Cancer Res Clin Oncol， 2011， 137（9）： 1293-1300. doi:10.1007/s00432-011-0989-x doi: 10.1007/s00432-011-0989-x
2	朱小玉. 脐血移植基础与临床［M］. 合肥：中国科学技术大学出版社， 2024.
3	SHANG Q N， YU X X， XU Z L， et al. Expanded clinical-grade NK cells exhibit stronger effects than primary NK cells against HCMV infection［J］. Cell Mol Immunol， 2023， 20（8）： 895-907. doi:10.1038/s41423-023-01046-5 doi: 10.1038/s41423-023-01046-5
4	DULPHY N， HAAS P， BUSSON M， et al. An unusual CD56（bright） CD16（low） NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation［J］. J Immunol， 2008， 181（3）： 2227-2237. doi:10.4049/jimmunol.181.3.2227 doi: 10.4049/jimmunol.181.3.2227
5	SWIECKI M， COLONNA M. The multifaceted biology of plasmacytoid dendritic cells［J］. Nat Rev Immunol， 2015， 15（8）： 471-485. doi:10.1038/nri3865 doi: 10.1038/nri3865
6	KLYUCHNIKOV E， ASENOVA S， KERN W， et al. Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia［J］. Leuk Lymphoma， 2010， 51（8）： 1450-1463. doi:10.3109/10428194.2010.496015 doi: 10.3109/10428194.2010.496015
7	FRY T J， MACKALL C L. Immune reconstitution following hematopoietic progenitor cell transplantation： challenges for the future［J］. Bone Marrow Transplant， 2005， 35 ： S53-S57. doi:10.1038/sj.bmt.1704848 doi: 10.1038/sj.bmt.1704848
8	STERN L， MCGUIRE H， AVDIC S， et al. Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell Transplantation［J］. Front Immunol， 2018， 9： 1672. doi:10.3389/fimmu.2018.01672 doi: 10.3389/fimmu.2018.01672
9	CORDÓN L， CHORÃO P， MARTÍN-HERREROS B， et al. Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies［J］. Ann Hematol， 2024， 103（7）： 2475-2484. doi:10.1007/s00277-024-05758-0 doi: 10.1007/s00277-024-05758-0
10	KLEIN A K， PATEL D D， GOODING M E， et al. T-Cell recovery in adults and children following umbilical cord blood transplantation［J］. Biol Blood Marrow Transplant， 2001， 7（8）： 454-466. doi:10.1016/s1083-8791(01)80013-6 doi: 10.1016/s1083-8791(01)80013-6
11	ABDEL-AZIM H， ELSHOURY A， MAHADEO K M， et al. Humoral Immune Reconstitution Kinetics after Allogeneic Hematopoietic Stem Cell Transplantation in Children： A Maturation Block of IgM Memory B Cells May Lead to Impaired Antibody Immune Reconstitution［J］. Biol Blood Marrow Transplant， 2017， 23（9）： 1437-1446. doi:10.1016/j.bbmt.2017.05.005 doi: 10.1016/j.bbmt.2017.05.005
12	TOMBLYN M， YOUNG J A， HAAGENSON M D， et al. Decreased infections in recipients of unrelated donor hematopoietic cell transplantation from donors with an activating KIR genotype［J］. Biol Blood Marrow Transplant， 2010， 16（8）： 1155-1161. doi:10.1016/j.bbmt.2010.02.024 doi: 10.1016/j.bbmt.2010.02.024
13	MCQUEEN K L， DORIGHI K M， GUETHLEIN L A， et al. Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched， sibling donor hematopoietic cell transplantation［J］. Hum Immunol， 2007， 68（5）： 309-323. doi:10.1016/j.humimm.2007.01.019 doi: 10.1016/j.humimm.2007.01.019
14	WILLEMZE R， RODRIGUES C A， LABOPIN M， et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia［J］. Leukemia， 2009， 23（3）： 492-500. doi:10.1038/leu.2008.365 doi: 10.1038/leu.2008.365
15	MARMONT A M， HOROWITZ M M， GALE R P， et al. T-cell depletion of HLA-identical transplants in leukemia［J］. Blood， 1991， 78（8）： 2120-2130. doi:10.1182/blood.v78.8.2120.bloodjournal7882120 doi: 10.1182/blood.v78.8.2120.bloodjournal7882120
16	BALLESTER O F， FANG T， RAPTIS A， et al. Adoptive immunotherapy with donor lymphocyte infusions and interleukin-2 after high-dose therapy and autologous stem cell rescue for multiple myeloma［J］. Bone Marrow Transplant， 2004， 34（5）： 419-423. doi:10.1038/sj.bmt.1704617 doi: 10.1038/sj.bmt.1704617
17	SCHMID C， LABOPIN M， NAGLER A， et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia： a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party［J］. J Clin Oncol， 2007， 25（31）： 4938-4945. doi:10.1200/jco.2007.11.6053 doi: 10.1200/jco.2007.11.6053
18	DEVILLIER R， GALIMARD J E， BLAISE D， et al. Peripheral blood stem cell versus bone marrow graft for patients ≥60 years undergoing reduced intensity conditioning haploidentical transplantation for acute myeloid leukemia in complete remission： An analysis of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation［J］. Am J Hematol， 2024， 99（7）： 1250-1256. doi:10.1002/ajh.27343 doi: 10.1002/ajh.27343
19	ZHU X， TANG B， SUN Z. Umbilical cord blood transplantation： Still growing and improving［J］. Stem Cells Transl Med， 2021， 10（Suppl 2）： S62-S74. doi:10.1002/sctm.20-0495 doi: 10.1002/sctm.20-0495
20	中华医学会血液学分会造血干细胞应用学组. 慢性移植物抗宿主病（cGVHD）诊断与治疗中国专家共识（2021年版）［J］. 中华血液学杂志， 2021， 42（4）： 265-275.
21	ZEISER R， POLVERELLI N， RAM R， et al. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease［J］. N Engl J Med， 2021， 385（3）： 228-238. doi:10.1056/nejmoa2033122 doi: 10.1056/nejmoa2033122
22	MAXIMOVA N， NISTICÒ D， RICCIO G， et al. Advantage of First-Line Therapeutic Drug Monitoring-Driven Use of Infliximab for Treating Acute Intestinal and Liver GVHD in Children： A Prospective， Single-Center Study［J］. Cancers （Basel）， 2023， 15（14）：3605. doi:10.3390/cancers15143605 doi: 10.3390/cancers15143605
23	KENNEDY G A， TEY S K， BUIZEN L， et al. A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis［J］. Blood， 2021， 137（14）： 1970-1979. doi:10.1182/blood.2020009050 doi: 10.1182/blood.2020009050
24	PIDALA J A， KIM J， KALOS D， et al. Ibrutinib for therapy of steroid-refractory chronic graft vs. host disease： A multicenter real-world analysis［J］. Blood Adv， 2024.doi： 10.1182/bloodadvances.2024014374 . doi: 10.1182/bloodadvances.2024014374
25	YAO S， HE L， SUOLITIKEN D， et al. Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis： Yes or no？［J］. Blood， 2024， 144（20）： 2107-2120. doi:10.1182/blood.2023023287 doi: 10.1182/blood.2023023287
26	XUAN L， WANG Y， YANG K， et al. Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia： Long-term follow-up of an open-label， multicentre， randomised， phase 3 trial［J］. Lancet Haematol， 2023， 10（8）： e600-e611. doi:10.1016/s2352-3026(23)00117-5 doi: 10.1016/s2352-3026(23)00117-5
27	ZHANG Z， HASEGAWA Y， HASHIMOTO D， et al. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation［J］. Bone Marrow Transplant， 2022， 57（5）： 775-780. doi:10.1038/s41409-022-01619-4 doi: 10.1038/s41409-022-01619-4
28	KENT A， SCHWARTZ M， MCMAHON C， et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse［J］. Bone Marrow Transplant， 2023， 58（8）： 849-854. doi:10.1038/s41409-023-01987-5 doi: 10.1038/s41409-023-01987-5
29	GARCIA J S， KIM H T， BROCK J， et al. Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML： Results of a Phase 1 Study［J］. Blood， 2022， 140（）： 917-919. doi:10.1182/blood-2022-157611 doi: 10.1182/blood-2022-157611
30	ORAN B， CHAMPLIN R E， THALL P F， et al. Phase II trial of venetoclax （Ven） in combination with azacitidine （AZA） as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation （SCT）［J］. Blood， 2022， 140（）： 10561-10562. doi:10.1182/blood-2022-159312 doi: 10.1182/blood-2022-159312
31	LEE J B， KHAN D H， HURREN R， et al. Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production［J］. Blood， 2021， 138（3）： 234-245. doi:10.1182/blood.2020009081 doi: 10.1182/blood.2020009081
32	WANG Y， HUANG B， LIANG T， et al. Venetoclax acts as an immunometabolic modulator to potentiate adoptive NK cell immunotherapy against leukemia［J］. Cell Rep Med， 2024， 5（6）： 101580. doi:10.1016/j.xcrm.2024.101580 doi: 10.1016/j.xcrm.2024.101580
33	BADER C S， PAVLOVA A， LOWSKY R， et al. Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD［J］. Blood Adv， 2024， 8（5）： 1105-1115. doi:10.1182/bloodadvances.2023011625 doi: 10.1182/bloodadvances.2023011625
34	RAMOS T L， BOLIVAR-WAGERS S， JIN S， et al. Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo［J］. Blood， 2023， 141（11）： 1337-1352. doi:10.1182/blood.2022018440 doi: 10.1182/blood.2022018440
35	HUANG R， CHEN T， WANG S， et al. Mesenchymal Stem Cells for Prophylaxis of Chronic Graft-vs-Host Disease After Haploidentical Hematopoietic Stem Cell Transplant： An Open-Label Randomized Clinical Trial［J］. JAMA Oncol， 2024， 10（2）： 220-226. doi:10.1001/jamaoncol.2023.5757 doi: 10.1001/jamaoncol.2023.5757
36	BEDNARSKI J J， ZIMMERMAN C， BERRIEN-ELLIOTT M M， et al. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant［J］. Blood， 2022， 139（11）： 1670-1683. doi:10.1182/blood.2021013972 doi: 10.1182/blood.2021013972
37	LEE K H， YOON S R， GONG J R， et al. The infusion of ex vivo， interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients-a randomized trial［J］. Leukemia， 2023， 37（4）： 807-819. doi:10.1038/s41375-023-01849-5 doi: 10.1038/s41375-023-01849-5
38	FISCHER K， VOELKL S， HEYMANN J， et al. Isolation and characterization of human antigen-specific TCR alpha beta+ CD4（-）CD8- double-negative regulatory T cells［J］. Blood， 2005， 105（7）： 2828-2835. doi:10.1182/blood-2004-07-2583 doi: 10.1182/blood-2004-07-2583
39	ZHANG Z X， MA Y， WANG H， et al. Double-negative T cells， activated by xenoantigen， lyse autologous B and T cells using a perforin/granzyme-dependent， Fas-Fas ligand-independent pathway［J］. J Immunol， 2006， 177（10）： 6920-6929. doi:10.4049/jimmunol.177.10.6920 doi: 10.4049/jimmunol.177.10.6920
40	GAO J F， MCINTYRE M S， JUVET S C， et al. Regulation of antigen-expressing dendritic cells by double negative regulatory T cells［J］. Eur J Immunol， 2011， 41（9）： 2699-2708. doi:10.1002/eji.201141428 doi: 10.1002/eji.201141428
41	PAN T， DING P， HUANG A， et al. Reconstitution of double-negative T cells after cord blood transplantation and its predictive value for acute graft-versus-host disease［J］. Chin Med J （Engl）， 2024， 137（10）： 1207-1217. doi:10.1097/cm9.0000000000002807 doi: 10.1097/cm9.0000000000002807
42	VASIC D， LEE J B， LEUNG Y， et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities［J］. Sci Immunol， 2022， 7（70）： eabl3642. doi:10.1126/sciimmunol.abl3642 doi: 10.1126/sciimmunol.abl3642
43	TANG B， LEE J B， CHENG S， et al. Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation： A first-in-human phase I study［J］. Am J Hematol， 2022， 97（7）： E264-E267. doi:10.1002/ajh.26564 doi: 10.1002/ajh.26564
44	GODDER K T， HENSLEE-DOWNEY P J， MEHTA J， et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation［J］. Bone Marrow Transplant， 2007， 39（12）： 751-757. doi:10.1038/sj.bmt.1705650 doi: 10.1038/sj.bmt.1705650
45	MCGUIRK J P， ABHYANKAR S H， GOSWAMI T， et al. Relapse Prophylaxis Post-Haploidentical Bone Marrow Transplantation and Cyclophosphamide （Haplo/Cy） By Infusion of Donor-Derived Expanded/Activated Gd T Cells： A Phase I Trial［J］. Blood， 2022， 140（）： 7464-7465. doi:10.1182/blood-2022-169819 doi: 10.1182/blood-2022-169819
46	NEELAPU S S， STEVENS D A， HAMADANI M， et al. A Phase 1 Study of ADI-001： Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 （γδ） T Cells in Adults with B-Cell Malignancies［J］. Blood， 2022， 140（）： 4617-4619. doi:10.1182/blood-2022-157400 doi: 10.1182/blood-2022-157400
47	JOHANNA I， STRAETEMANS T， HEIJHUURS S， et al. Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells［J］. J Immunother Cancer， 2019， 7（1）： 69. doi:10.1186/s40425-019-0558-4 doi: 10.1186/s40425-019-0558-4
48	STRAETEMANS T， KIERKELS G J J， DOORN R， et al. GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR［J］. Front Immunol， 2018， 9： 1062. doi:10.3389/fimmu.2018.01062 doi: 10.3389/fimmu.2018.01062
49	KAWASE T， MATSUO K， KASHIWASE K， et al. HLA mismatch combinations associated with decreased risk of relapse： implications for the molecular mechanism［J］. Blood， 2009， 113（12）： 2851-2858. doi:10.1182/blood-2008-08-171934 doi: 10.1182/blood-2008-08-171934
50	YABE T， AZUMA F， KASHIWASE K， et al. HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation［J］. Leukemia， 2018， 32（1）： 168-175. doi:10.1038/leu.2017.202 doi: 10.1038/leu.2017.202
51	ZHAO X Y， CHANG Y J， ZHAO X S， et al. Recipient expression of ligands for donor inhibitory KIRs enhances NK-cell function to control leukemic relapse after haploidentical transplantation［J］. Eur J Immunol， 2015， 45（8）： 2396-2408. doi:10.1002/eji.201445057 doi: 10.1002/eji.201445057
52	SCOTT B L， PASQUINI M C， LOGAN B R， et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes［J］. J Clin Oncol， 2017， 35（11）： 1154-1161. doi:10.1200/jco.2016.70.7091 doi: 10.1200/jco.2016.70.7091
53	GAO L， WEN Q， CHEN X， et al. Effects of priming with recombinant human granulocyte colony-stimulating factor on conditioning regimen for high-risk acute myeloid leukemia patients undergoing human leukocyte antigen-haploidentical hematopoietic stem cell transplantation： A multicenter randomized controlled study in southwest China［J］. Biol Blood Marrow Transplant， 2014， 20（12）： 1932-1939. doi:10.1016/j.bbmt.2014.08.001 doi: 10.1016/j.bbmt.2014.08.001
54	BLEAKLEY M， HEIMFELD S， LOEB K R， et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts［J］. J Clin Invest， 2015， 125（7）： 2677-2689. doi:10.1172/jci81229 doi: 10.1172/jci81229
55	RUGGERI L， CAPANNI M， URBANI E， et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants［J］. Science， 2002， 295（5562）： 2097-2100. doi:10.1126/science.1068440 doi: 10.1126/science.1068440
56	MARTELLI M F， DI IANNI M， RUGGERI L， et al. "Designed" grafts for HLA-haploidentical stem cell transplantation［J］. Blood， 2014， 123（7）： 967-973. doi:10.1182/blood-2013-10-531764 doi: 10.1182/blood-2013-10-531764

[1]	Haiyang LU,Weili ZHAO,Xiaoxia. HU. Gut microbiota modulates immune reconstitution in allogeneic hematopoietic stem cell transplantation [J]. The Journal of Practical Medicine, 2025, 41(5): 628-633.
[2]	PENG Yingnan, BIAN Zhilei, CAO Weijie, LI Li, ZHANG Suping, WAN Dingming.. Efficacy and safety study of posaconazole and voriconazole for the prevention of invasive fungal infections after allogeneic hematopoietic stem cell transplantation [J]. The Journal of Practical Medicine, 2023, 39(6): 742-746.
[3]	Yupei ZHANG,Xinsheng XIE,Yajie SHI,Weijie CAO,Rong GUO,Dingming. WAN. Curative effect analysis of transplantation in patients with myelodysplastic syndrome with ASXL1 gene mutation [J]. The Journal of Practical Medicine, 2023, 39(23): 3087-3092.

Advances in immunological research on hematopoietic stem cell transplantation

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 56

Related Articles 3

Recommended Articles

Metrics

Comments